A revolutionary new device that burns out liver tumours has gained CE Mark approval.
The new PMTA Applicator for tumour ablation from UK company Acculis will shortly be available in the UK.
The applicator is a single high-power, high-frequency 2.45GHz microwave needle that burns a 5cm sphere of tissue in 5 minutes – over three times as fast as conventional radiofrequency-based systems or lower-frequency microwave systems.
“This system gives surgeons and interventionalists the ability to treat previously inoperable patients and early data suggests significantly improved clinical outcomes for tumour control,” said David Lloyd, who created the system along with Professor Nigel Cronin and his microwave science team at the University of Bath.
“This system gives surgeons and interventionalists the ability to treat previously inoperable patients, and early data suggests significantly improved clinical outcomes for tumour control.”
The new device is the latest in a series from the company. “Our Acculis MTA system revolutionises ablative therapy. Its sheer speed and power allow decisive new therapy for patients for whom there was previously little hope,” said Acculis CEO Stuart McIntyre.
“We have been delighted with the results of our first devices, launched in 2008 and 2009, to the liver surgery community and this new device makes the technology available to the whole interventional radiology community. We expect first deliveries in the UK and Europe over the coming weeks.”
According to Acculis, new clinical data show promising outcomes when compared to current ablative therapies such as radiofrequency ablation.
Based in Denmead, Hampshire, Acculis is a specialist medical device company developing microwave energy ablation systems for oncology applications.